INTRODUCTION
Allogeneic hematopoietic cell transplantation (HCT) is an effective therapy for many patients with acute myeloid leukemia (AML) in first or subsequent complete remission (CR). 1, 2 However, even in the absence of morphologically detectable disease at the time of transplantation, relapse remains a major cause of treatment failure post-HCT, 2 demonstrating that microscopybased evaluations are incapable of detecting clinically relevant amounts of tumor cells. Over the last 2 decades, several techniques were developed that enable the sensitive quantification of minimal amounts of residual disease (MRD) in patients with AML in morphological remission. [3] [4] [5] [6] The most widely exploited method in AML other than acute promyelocytic leukemia (APL) is multiparameter flow cytometry (MFC)-based since AML cells feature immunophenotypic abnormalities ("leukemia-associated immunophenotypes [LAIP]") that can be used to distinguish them from normal hematopoietic cells in the vast majority (>90%) of cases with high sensitivity. [3] [4] [5] [6] Previous studies from our group 7 and others [8] [9] [10] [11] [12] [13] have demonstrated that MFC-detectable MRD at the time of autologous or myeloablative allogeneic HCT is a powerful, independent predictor of subsequent relapse and shorter survival for AML patients in CR. These studies have exclusively or primarily focused on patients undergoing HCT in first CR (CR1). The relationship between MRD and outcome is much less studied for patients in second CR (CR2). Furthermore, while several studies in patients with acute lymphoblastic leukemia suggest that the association between MRD and risk of post-HCT relapse is "dose-dependent", 6 the quantitative impact of MRD levels on outcome in AML has not been well studied. To address these uncertainties, we investigated the quantitative significance of MRD in 253 consecutive patients who underwent allogeneic myeloablative HCT for AML in CR1 or CR2 at our institution.
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PATIENTS AND METHODS

Study Cohort
Patients of all ages, identified from our computerized database, were included in this study if they had AML in CR1 or CR2 with or without incomplete peripheral blood count recovery (i.e CRi1 or CRi2) based on morphologic criteria 14, 15 (i.e. regardless of the presence of MRD) at the time of HCT, underwent myeloablative conditioning, had either a matched sibling or unrelated donor, and received the first transplant. We included all consecutive patients meeting these criteria if they underwent pre-HCT work up from late April 2006, the time a refined MFC-based MRD detection method was introduced at our institution and utilized routinely during the pre-HCT work-up in all patients, until November 2011. Results on the first 99 CR1 patients have been reported previously. 7 We used the 2008 WHO criteria to define AML 16 and the refined United Kingdom Medical Research Council (MRC) criteria to assign cytogenetic risk. 17 Cytogenetic analysis was performed with the G-banding method. Treatment response criteria were used as proposed by International Working Groups. 14, 15 Because many patients were referred from outside institutions, molecular testing for NPM1, FLT3, and CEBPA mutations was not uniformly available. Chronic graft-versus-host disease (cGVHD) was diagnosed using National Institutes of Health consensus criteria. 18 Information on post-transplant outcomes was captured via the Long-Term Follow-Up Program through medical records from our outpatient clinic and local clinics that provided primary care for patients. All patients were treated on Institutional Review Board-approved protocols and gave consent in accordance with the Declaration of Helsinki. Follow-up was current as of April 1, 2013.
MFC Detection of MRD
Ten-color MFC was performed on bone marrow aspirates obtained as routine baseline assessment before HCT with a panel consisting of three tubes as follows:
Blue (PB), CD15-FITC, CD33-Phycoerythrin (PE), CD19-PE-Texas Red (PE-TR), CD117-PECy5, CD13-PE-Cy7, CD38-Alexa 594 (A594), CD34-allophycocyanin (APC), CD71-APC-A700
and CD45-APC-H7. (2) HLA-DR-PB, CD64-FITC, CD123-PE, CD4-PE-TR, CD14-PE-Cy5.5, CD13-PE-Cy7, CD38-A594, CD34-APC, CD16-APC-A700 and CD45-APC-H7. (3) CD56-Alexa 488, CD7-PE, CD5-PE-Cy5, CD33-PE-Cy7, CD38-A594, CD34-APC and CD45-APC-H7. All antibodies were obtained from Beckman-Coulter (Fullerton, CA) or Becton-Dickinson (San Jose, CA). Up to 1 million events per tube were acquired on a custom-built LSRII and data compensation and analysis performed using software developed in our laboratory (WoodList).
MRD was identified as a population showing deviation from the normal patterns of antigen
For personal use only. on May 6, 2017. by guest www.bloodjournal.org From expression seen on specific cell lineages at specific stages of maturation as compared with either normal or regenerating marrow. Thus, this approach was not restricted to the use of LAIP, as immunophenotypic data from initial disease presentation was only available for a subset of patients; however, if available, such LAIP abnormalities were also assessed in the pre-HCT specimens. The routine sensitivity of this assay was estimated at 0.1% although a higher level of sensitivity was possible for a subset of leukemias featuring more frankly aberrant immunophenotypes. When identified, the abnormal population was quantified as a percentage of the total CD45 + white cell events. As done previously, and as pre-specified, any level of residual disease was considered MRD pos .
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Statistical Analysis
Unadjusted probabilities of overall survival (OS) and disease-free survival (DFS) were estimated using the Kaplan-Meier method, and probabilities of NRM and relapse were summarized using cumulative incidence estimates. NRM was defined as death without prior relapse and was considered a competing risk for relapse, while relapse was a competing risk for NRM. All outcomes were treated as time-to-event endpoints. 
RESULTS
Patient Characteristics
We identified 253 patients undergoing first myeloablative HCT from a matched-related or an Tables 1 and 2 
Association between MRD Status and Post-HCT Outcome
There were a total of 93 deaths, 75 relapses, and 35 NRM events contributing to the probability estimates for OS, DFS, relapse, and NRM stratified by MRD status for CR1 and CR2 patients. Figure 1B ). Three-year estimates of relapse among CR1 patients were 21% (14-28%) and 59% (41-72%), respectively, and 19% (9-31%) and 68% (41-85%), respectively, among CR2 patients ( Figure 1C ). Finally, among CR1 patients, the 3-year estimates of NRM where 11% (6-16%) and 22% (10-37%) for MRD neg and MRD pos patients, respectively; among CR2 patients, 3-year NRM was estimated to be 12% (5-23%) and 11% (2-30%), respectively ( Figure 1D 
Pre-HCT MRD Status as Independent Prognostic Factor
Univariate regression models for OS, DFS, relapse, and NRM were fit to assess the relevance of MRD as prognostic factor. As summarized in Table 4 , being MRD pos at the time of HCT was significantly associated with shorter OS (P<0.001) and DFS (P<0.001) as well as an increased risk of relapse (P<0.001) and NRM (P=0.017). The association of MRD with outcome among patients in CR1 was similar to that among patients in CR2 (e.g., P=0.63, P=0.77 tests of interaction for mortality, relapse). Among patients with MRD, there was no statistically significant evidence that increasing levels of MRD were associated with increasing risk of any outcome.
This was true when MRD was evaluated as a continuous variable (on a log scale) or as a test for trend across three groups: ≤ 0.1% (n=14), >0.1-1% (n=24), and >1% (n=16) (Figure 2 (Table 5) .
We then performed similar multivariate models restricting the study cohort to those 216 patients who met peripheral blood criteria for CR as proposed by the International Working Groups. 14, 15 We significantly worse outcome with a 3-year cumulative incidence of relapse that approximates 60%, resulting in an estimated survival of approximately 30%. The current study extends these findings to AML patients transplanted in morphologic CR2. Specifically, in our cohort, the outcomes of MRD neg patients were similar for CR1 and CR2 patients. Likewise, the outcomes of MRD pos patients were similar for CR1 and CR2 patients. At first glance, the relatively similar outcome for CR1 and CR2 patients may be surprising. However, our data suggest that, rather than the number of remission, MRD status (and, therefore, the susceptibility to preceding chemotherapy) is the dominating pre-HCT factor associated with post-HCT relapse risk and outcome.
MRD neg and MRD pos patients differed in many factors that predict outcome in AML, including cytogenetic disease risk and type of AML (secondary vs. primary). There were also notable differences among these patient subsets with regard to several pre-HCT factors, such as pre-HCT blood count recovery or abnormal pre-HCT karyotype, that we previously showed to be associated with increased risk of post-HCT outcome in univariate analyses for AML patients undergoing transplantation in CR1. 7 However, our multivariate models indicate that pre-HCT MRD is an adverse risk factor for HCT outcome for both CR1 and CR2 patients even after adjusting for these other factors. With the caveat that we did not have full molecular characterization of all cases, these multivariable models suggest that MRD is the decisive pre-HCT factor for post-HCT outcome and the only one independently associated with increased relapse risk and shorter OS and DFS (Table 5 ).
Our data confirm previous studies showing that the development of cGVHD is associated with a reduced risk of relapse in AML patients undergoing myeloablative HCT. 19, 20 At least in our cohort, we were unable to discern any statistically significant difference in the magnitude of this GVL effect between MRD pos and MRD neg patients. This finding suggests that the high relapse risk post allogeneic transplant for MRD pos patients is not due to less strong GVL effects in this
. This observation is somewhat reminiscent of recent data indicating that the allogeneic HCT-associated reduction of relapse and improvement of survival in patients with monosomal karyotype AML is relatively similar to that of patients with less unfavorable AML subtypes. 21 The threshold below or above which patients should be considered MRD neg or MRD pos based on flow cytometric assessment of residual tumor amounts has been controversial, and several groups have proposed the use of different thresholds above the minimal detection limit as optimal cutoffs for the best segregation of patients into categories of post-HCT relapse risk rather than using the technical detection limit of the MRD assay as threshold. 5, 6 Our findings from the current study lead us to question the usefulness of this approach. Specifically, in our cohort, the risk of relapse among MRD pos patients with a level ≤ 0.1% (a level considered "negative" in recent series 12,13 ) was significantly higher than that among patients in which we were unable to detect any MRD. On the other hand, among patients with MRD, there was no statistically significant evidence that increasing levels of MRD were associated with increasing risk of any outcome. Of course, despite the size of our study cohort, the number of MRD pos patients was still relatively modest, and such an association cannot be ruled out with certainty.
In fact, our HR estimates for patients with MRD >1% were consistently (but statistically nonsignificantly) higher than those with MRD ≤0.1%, and the study of larger numbers of patients may indeed yield a statistically significant quantitative between these patient subsets.
Nonetheless, these data suggest that MRD pos patients (regardless of the level of MRD) are more similar to each other than MRD neg patients are to MRD pos patients with the lowest detectable levels of MRD, an observation that would support the approach of using the MRD assay detection limit as a threshold to distinguish MRD neg from MRD pos as is currently our institution's approach. As stated, we a priori defined MRD pos as any level of residual disease.
While the number of MRD pos patients in the different residual disease categories was not sufficient to evaluate the full range of association, it is noteworthy that when assessing each possible cutoff within the ≤ 0.1% category, we found the 0 vs. >0 split to be the most statistically significant.
In our previous study, we observed that, in addition to higher risk of relapse and inferior OS and DFS, MRD pos patients with AML transplanted in CR1 also had a higher risk of NRM relative to MRD neg patients. 7 Our present analysis on the expanded CR1 and CR2 AML patient cohort confirms this initial finding, indicating an approximately 2-fold increased risk of NRM for MRD pos For personal use only. on May 6, 2017. by guest www.bloodjournal.org From patients that, however, did not remain statistically significant after multivariate adjustment. We speculate that differences in the type and timing of pre-HCT therapy may account for this increase in NRM, but further studies will be required to better understand this relationship.
In summary, our findings suggest that the negative impact of MRD on outcome among AML patients in CR2 is similar to the negative impact seen in patients in CR1. Our data indicate that outcomes of MRD neg AML patients are excellent after myeloablative HCT in either CR1 or CR2.
An important question to address in future, well-controlled studies is whether less intensive consolidation strategies (e.g. chemotherapy, autologous HCT, or reduced-intensity allogeneic HCT) could provide a similar level of disease control with lower risks for treatment-related toxicities and mortality for these low-risk (i.e. MRD neg ) patients. On the other hand, even patients with minute amounts of MRD (≤0.1%) have significantly worse outcomes than MRD neg patients.
Observations by others have suggested that the outcomes of AML patients with pre-HCT MRD may be better when they undergo allogeneic rather than autologous HCT, 
